242 related articles for article (PubMed ID: 17315170)
1. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas.
Saussez S; Camby I; Toubeau G; Kiss R
Head Neck; 2007 Sep; 29(9):874-84. PubMed ID: 17315170
[TBL] [Abstract][Full Text] [Related]
2. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy.
Saussez S; Lorfevre F; Lequeux T; Laurent G; Chantrain G; Vertongen F; Toubeau G; Decaestecker C; Kiss R
Oral Oncol; 2008 Jan; 44(1):86-93. PubMed ID: 17350328
[TBL] [Abstract][Full Text] [Related]
3. Expression of galectins in head and neck squamous cell carcinoma.
Gillenwater A; Xu XC; el-Naggar AK; Clayman GL; Lotan R
Head Neck; 1996; 18(5):422-32. PubMed ID: 8864733
[TBL] [Abstract][Full Text] [Related]
4. Protective mechanisms of head and neck squamous cell carcinomas from immune assault.
Young MR
Head Neck; 2006 May; 28(5):462-70. PubMed ID: 16284974
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC
J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933
[TBL] [Abstract][Full Text] [Related]
6. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas.
Saussez S; Decaestecker C; Lorfevre F; Chevalier D; Mortuaire G; Kaltner H; André S; Toubeau G; Gabius HJ; Leroy X
Histopathology; 2008 Mar; 52(4):483-93. PubMed ID: 18315601
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?
Alhamarneh O; Amarnath SM; Stafford ND; Greenman J
Head Neck; 2008 Feb; 30(2):251-61. PubMed ID: 18172882
[TBL] [Abstract][Full Text] [Related]
8. Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue.
Alves PM; Godoy GP; Gomes DQ; Medeiros AM; de Souza LB; da Silveira EJ; Vasconcelos MG; Queiroz LM
Pathol Res Pract; 2011 Apr; 207(4):236-40. PubMed ID: 21397408
[TBL] [Abstract][Full Text] [Related]
9. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
Saussez S; Cucu DR; Decaestecker C; Chevalier D; Kaltner H; André S; Wacreniez A; Toubeau G; Camby I; Gabius HJ; Kiss R
Ann Surg Oncol; 2006 Jul; 13(7):999-1009. PubMed ID: 16788763
[TBL] [Abstract][Full Text] [Related]
10. Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7.
Cludts S; Decaestecker C; Mahillon V; Chevalier D; Kaltner H; André S; Remmelink M; Leroy X; Gabius HJ; Saussez S
Anticancer Res; 2009 Dec; 29(12):4933-40. PubMed ID: 20044599
[TBL] [Abstract][Full Text] [Related]
11. Varied expression and localization of multiple galectins in different cancer cell lines.
Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
Sioud M; Mobergslien A; Boudabous A; Fløisand Y
Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 upregulation during tumor progression in head and neck cancer.
Saussez S; Decaestecker C; Mahillon V; Cludts S; Capouillez A; Chevalier D; Vet HK; André S; Toubeau G; Leroy X; Gabius HJ
Laryngoscope; 2008 Sep; 118(9):1583-90. PubMed ID: 18677282
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma.
Plzák J; Betka J; Smetana K; Chovanec M; Kaltner H; André S; Kodet R; Gabius HJ
Eur J Cancer; 2004 Oct; 40(15):2324-30. PubMed ID: 15454259
[TBL] [Abstract][Full Text] [Related]
15. [Galectins in squamous cell carcinomas of the head and neck cancers].
Cada Z; Plzák J; Chovanec M; Dvoránková B; Lacina L; Szabó P; Smetana K; Betka J
Cas Lek Cesk; 2008; 147(11):559-63. PubMed ID: 19097359
[TBL] [Abstract][Full Text] [Related]
16. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression.
Patel V; Hood BL; Molinolo AA; Lee NH; Conrads TP; Braisted JC; Krizman DB; Veenstra TD; Gutkind JS
Clin Cancer Res; 2008 Feb; 14(4):1002-14. PubMed ID: 18281532
[TBL] [Abstract][Full Text] [Related]
18. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.
Rapoport EM; André S; Kurmyshkina OV; Pochechueva TV; Severov VV; Pazynina GV; Gabius HJ; Bovin NV
Glycobiology; 2008 Apr; 18(4):315-24. PubMed ID: 18256179
[TBL] [Abstract][Full Text] [Related]
19. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Bergmann C; Strauss L; Zeidler R; Lang S; Whiteside TL
Cancer Res; 2007 Sep; 67(18):8865-73. PubMed ID: 17875728
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3, an endogenous lectin, as a tool for monitoring cell differentiation in head and neck carcinomas with implications for lectin-glycan functionality.
Betka J; Plzák J; Smetana K; Gabius HJ
Acta Otolaryngol; 2003 Jan; 123(2):261-3. PubMed ID: 12701754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
